Comprehensive analysis of eosinophils and type 2 innate lymphoid cells in patients with severe asthma before and after mepolizumab treatment - Comprehensive analysis of eosinophils and type 2 innate lymphoid cells in patients with severe asthma before and after mepolizumab treatment (MEISEA)

Keio University0 sites40 target enrollmentNovember 24, 2023

Overview

No summary available.

Registry

who.int

Start Date

November 24, 2023

End Date

March 31, 2026

Last Updated

2 years ago

Study Type

Others,meta-analysis etc

Sex

All

Sponsor

•Patients are not eligible for this study if they met any of the following criteria Has previously been treated with mepolizumab before the study Has a history of acute viral infection up to 4 weeks prior to blood sampling Has been treated with systemic corticosteroids including methylprednisolone up to 4 weeks prior to blood sampling History of widespread lung disease Has cancer/malignancy under treatment During the period of pregnancy Individuals whom the principal investigators judge as inappropriate registers Healthy volunteers are not eligible for this study if they met any of the following criteria: Has a history of acute viral infection up to 4 weeks prior to blood sampling Individuals whom the principal investigators judge as inappropriate registers